{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:10:50Z","timestamp":1790935850133,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Baricitinib demonstrated efficacy in treating adults with moderate\u2010to\u2010severe atopic dermatitis (AD) in Phase 3 clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine long\u2010term efficacy of baricitinib combined with topical corticosteroids (TCS) in adult patients from a Phase 3 study, BREEZE\u2010AD7 (NCT03733301), enrolled in ongoing extension study, BREEZE\u2010AD3 (NCT03334435).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Upon BREEZE\u2010AD7 completion, responders or partial responders (RPR [vIGA\u2010AD\u2122 \u22642]) receiving baricitinib 2\u2010mg or 4\u2010mg\u2009+\u2009TCS maintained their original treatment doses in BREEZE\u2010AD3. Nonresponders (NR; vIGA\u2010AD 3,4) receiving baricitinib 2\u2010mg were rerandomized 1:1 to baricitinib 2\u2010mg or 4\u2010mg; NR receiving baricitinib 4\u2010mg remained on same dose. Integrated data from all patients (RPR\u2009+\u2009NR\u00a0=\u00a0baricitinib 4\u2010mg intent\u2010to\u2010treat [ITT] cohort) receiving continuous baricitinib 4\u2010mg in BREEZE\u2010AD7 through BREEZE\u2010AD3 were analysed, along with baricitinib 4\u2010mg or 2\u2010mg RPR cohorts. Primary endpoint was proportion of patients with vIGA\u2010AD (0,1) at Weeks 16, 36 and 52 (Weeks 32, 52 and 68 of continuous therapy). Additional outcomes included improvement in EASI75 and Itch NRS (up to Week 32). Missing data were imputed by last observation carried forward.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In baricitinib 4\u2010mg ITT cohort (<jats:italic>N<\/jats:italic>\u00a0=\u00a0102), proportions of patients achieving vIGA\u2010AD (0,1) at Week 32, Week 52, and Week 68 were 21.6%, 26.5% and 23.5%; EASI75 were 46.1%, 40.2% and 43.1%, respectively. Itch NRS \u22654\u2010point improvement (Itch \u22654) were 47.3% at Week 16 and 40.6% at Week 32.<\/jats:p><jats:p>In baricitinib 4\u2010mg RPR cohort (<jats:italic>N<\/jats:italic>\u00a0=\u00a063), proportions of patients achieving vIGA\u2010AD (0,1) at Week 32, Week 52 and Week 68 were 31.7%, 33.3% 34.9%, respectively; EASI75 were 57.1%, 49.2% and 49.2%, respectively. Itch \u22654 were 53.6% at Week 16 and 46.4% at Week 32. Corresponding proportions for baricitinib 2\u2010mg RPR cohort (<jats:italic>N<\/jats:italic>\u00a0=\u00a053) for vIGA\u2010AD (0,1) were 39.6%, 45.3% and 30.2%; EASI75 were 77.4%, 69.8% and 58.5%, respectively. Itch \u22654 were 56.3% at Week 16 and 47.9% at Week 32.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Baricitinib 4\u2010mg and 2\u2010mg combined with TCS maintained clinically meaningful sustained efficacy over 68\u2009weeks of continuous treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18816","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:20:15Z","timestamp":1671009615000},"page":"1036-1045","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long\u2010term efficacy (up to 68\u2009weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate\u2010to\u2010severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE\u2010AD7"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[{"name":"Department of Dermatology George Washington University School of Medicine  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-1743","authenticated-orcid":false,"given":"Jacob Pontoppidan","family":"Thyssen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bispebjerg Hospital, University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy E.","family":"Cardillo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Colvin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun\u2010Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Chen","sequence":"additional","affiliation":[{"name":"Tigermed  Somerset New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pediatrics University of California San Diego School of Medicine and Rady Children's Hospital  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"issue":"8","key":"e_1_2_11_3_1","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena\u2010Woods C","year":"2017","journal-title":"Am J Manag Care"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.06.010"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12154"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.076"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.016"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14567"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0413-2"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01877-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0128-z"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T18:26:42Z","timestamp":1692642402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/jdv.18816"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18816","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"2022-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}